Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Plans Avastin/Tarceva Combo Filing; Avastin Warning Hurts Growth

Executive Summary

Genentech and OSI Pharmaceuticals will be meeting with FDA early in 2005 to discuss filing plans for Tarceva (erlotinib) in pancreatic cancer
Advertisement

Related Content

Bayer Nexavar Safety Profile Fuels Research In Multiple Cancer Indications
Oncologics Will Need Dual Genetic Tests For Optimally Targeted Treatments
Orencia Marketing Likely To Focus On Broader Mechanism Of Action
American Society Of Clinical Oncology Highlights
AstraZeneca To Revisit Iressa Dosing Following Failed Survival Study
AstraZeneca To Revisit Iressa Dosing Following Failed Survival Study
Genentech Rituxan Promotions Under Investigation By DoJ
Genentech Avastin Labeling Will Reflect New Data On Thromboembolic Events
Avastin, Erbitux Costs Invite Price Controls, Former NCI Deputy Says
Rituxan Rheumatoid Arthritis sBLA Filing Expected In Late 2005

Topics

Advertisement
UsernamePublicRestriction

Register

PS045250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel